, , , , ,

Institutional Investors Take Notice of Cannabis Industry, Marking a Crucial Step Towards Mainstream Acceptance

Institutional Investors Take Notice of Cannabis Industry

For the first time, institutional equity investors are willing to engage in conversations with cannabis companies, a significant step forward for an industry long shunned by Wall Street. This development was revealed by Boris Jordan, CEO of Curaleaf, at a recent conference. While it’s not yet a sign of investment, it marks a crucial first step towards building a robust shareholder base.

Jordan’s company is deliberately delaying its uplisting to major exchanges, prioritizing federal regulatory clarity and a strong foundation of shareholders. This approach is a departure from the typical strategy of listing first and then hoping for investor demand. Instead, Curaleaf is proactively lining up a pool of long-term shareholders ahead of its listing event.

The shift towards institutional investors is a significant milestone for the cannabis industry, which has historically relied on private capital and debt financing. Jordan’s comments highlight the importance of compliance departments, which often need internal sign-off before investing in cannabis companies.

Industry observers believe that this development signals a new chapter for cannabis finance. The sector needs platforms valued at $10 billion to $15 billion to attract institutional capital, and consolidation is likely to play a key role in achieving this goal. Jordan estimates that combining larger operators could unlock $150 million to $200 million in synergies.

Curaleaf’s $1 billion European business, built to EU GMP standards, is a key part of this scale argument. The company’s strategy is focused on long-term value creation, and it believes that increased access to institutional capital will accelerate the industry’s next phase of growth.

While this development is significant, it’s not yet a guarantee of institutional investment. Compliance departments still need to sign off, and federal rescheduling and regulatory clarity are still pending. However, the fact that the CEO of one of the world’s largest cannabis companies now views a returned phone call from an institutional investor as newsworthy is a sign of the industry’s progress and a potential turning point in its development.